<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1529" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1529/" /><meta name="ncbi_pagename" content="Huntington Disease-Like 2 - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Huntington Disease-Like 2 - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Huntington Disease-Like 2" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2019/06/27" /><meta name="citation_author" content="David G Anderson" /><meta name="citation_author" content="Amanda Krause" /><meta name="citation_author" content="Russell L Margolis" /><meta name="citation_pmid" content="20301701" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1529/" /><meta name="citation_keywords" content="Junctophilin-3" /><meta name="citation_keywords" content="JPH3" /><meta name="citation_keywords" content="Huntington Disease-Like 2" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Huntington Disease-Like 2" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="David G Anderson" /><meta name="DC.Contributor" content="Amanda Krause" /><meta name="DC.Contributor" content="Russell L Margolis" /><meta name="DC.Date" content="2019/06/27" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1529/" /><meta name="description" content="Huntington disease-like 2 (HDL2) typically presents in midlife with a relentless progressive triad of movement, emotional, and cognitive abnormalities which lead to death within ten to 20 years. HDL2 cannot be differentiated from Huntington disease clinically. Neurologic abnormalities include chorea, hypokinesia (rigidity, bradykinesia), dysarthria, and hyperreflexia in the later stages of the disease. There is a strong correlation between the duration of the disease and the progression of the motor and cognitive disorder." /><meta name="og:title" content="Huntington Disease-Like 2" /><meta name="og:type" content="book" /><meta name="og:description" content="Huntington disease-like 2 (HDL2) typically presents in midlife with a relentless progressive triad of movement, emotional, and cognitive abnormalities which lead to death within ten to 20 years. HDL2 cannot be differentiated from Huntington disease clinically. Neurologic abnormalities include chorea, hypokinesia (rigidity, bradykinesia), dysarthria, and hyperreflexia in the later stages of the disease. There is a strong correlation between the duration of the disease and the progression of the motor and cognitive disorder." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1529/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/hd-l2/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1529/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8AC4A5DFC86971000000000768039A.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1529_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1529_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/huntington/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/huppke-brendel/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1529_"><span class="title" itemprop="name">Huntington Disease-Like 2</span></h1><p class="contrib-group"><span itemprop="author">David G Anderson</span>, MBBCh, FCN, MMed, <span itemprop="author">Amanda Krause</span>, MBBCh, PhD, and <span itemprop="author">Russell L Margolis</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK1529_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1529_ai__"><div class="contrib half_rhythm"><span itemprop="author">David G Anderson</span>, MBBCh, FCN, MMed<div class="affiliation small">Consultant Neurologist, University of the Witwatersrand<br />Donald Gordon Medical Centre<br />Johannesburg, South Africa<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gruboj.oruen@divad" class="oemail">gruboj.oruen@divad</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Amanda Krause</span>, MBBCh, PhD<div class="affiliation small">Head, Division of Human Genetics<br />National Health Laboratory Service and School of Pathology<br />Faculty of Health Sciences<br />University of the Witwatersrand<br />Johannesburg, South Africa<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="az.ca.stiw@esuark.adnama" class="oemail">az.ca.stiw@esuark.adnama</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Russell L Margolis</span>, MD<div class="affiliation small">Professor of Psychiatry and Neurology, Laboratory of Genetic Neurobiology<br />Department of Psychiatry<br />Johns Hopkins University School of Medicine<br />Baltimore, Maryland<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.imhj@ilogramr" class="oemail">ude.imhj@ilogramr</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">January 30, 2004</span>; Last Update: <span itemprop="dateModified">June 27, 2019</span>.</p><p><em>Estimated reading time: 22 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="hd-l2.Summary" itemprop="description"><h2 id="_hd-l2_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Huntington disease-like 2 (HDL2) typically presents in midlife with a relentless progressive triad of movement, emotional, and cognitive abnormalities which lead to death within ten to 20 years. HDL2 cannot be differentiated from Huntington disease clinically. Neurologic abnormalities include chorea, hypokinesia (rigidity, bradykinesia), dysarthria, and hyperreflexia in the later stages of the disease. There is a strong correlation between the duration of the disease and the progression of the motor and cognitive disorder.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of HDL2 rests on positive family history, characteristic clinical findings, and the detection of an expansion of 40 or more CTG trinucleotide repeats in <i>JPH3</i>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Treatment is symptomatic and is presumably similar to that for HD and other neurodegenerative disorders &#x02013; although this must be considered speculative pending objective data. Pharmacologic agents that may suppress abnormal movements include tetrabenazine and its derivatives, low-dose neuroleptic agents such as fluphenazine and haloperidol. Antidepressants, antipsychotics, mood stabilizers (lithium, valproic acid, carbamazepine, and lamotrigine), and occasionally stimulants may improve psychiatric manifestations. Education about the course of disease and environmental interventions (regular schedules, use of lists to assist memory). Remove loose rugs and clutter from the individual's home and minimize or eliminate the need for stairs to help prevent falls and other injuries; driving may need to be curtailed or limited to prevent risk of accidents; food should be prepared in such a manner as to prevent choking.</p><p><i>Surveillance:</i> Monitor: nutrition and swallowing in order to implement feeding changes when necessary to minimize risk of aspiration; gait and use appropriate strategies or devices to minimize falls; driving to assure that <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals do not present a danger to themselves or others; mood and irritability, such that measures to decrease the risk of suicide, other behavioral abnormalities, and distress may be implemented.</p><p><i>Agents/circumstances to avoid</i>: Any agents that increase ataxia should be used with caution; avoid polypharmacy, which may exacerbate delirium.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>HDL2 is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. HDL2 resulting from a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has not been reported but is theoretically possible. Offspring of an individual with HDL2 have a 50% chance of inheriting the HDL2-causing <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>. Predictive testing in asymptomatic adults at risk is available but requires careful thought (including pre- and post-test <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a>) as there is currently no cure for the disorder. Predictive testing is not considered appropriate for asymptomatic at-risk individuals younger than age 18 years. Prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible once an HDL2-causing expansion has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member.</p></div></div><div id="hd-l2.Diagnosis"><h2 id="_hd-l2_Diagnosis_">Diagnosis</h2><div id="hd-l2.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Huntington disease-like 2 (HDL2) <b>should be suspected</b> in individuals &#x02013;particularly of African descent or with African ancestry (even if distant) &#x02013; who present with clinical features typical of <a href="/books/n/gene/huntington/">Huntington disease</a> (HD) but do not have a disease-causing CAG expansion (i.e., <a class="def" href="/books/n/gene/glossary/def-item/reduced-penetrance-allele/">reduced-penetrance allele</a> or <a class="def" href="/books/n/gene/glossary/def-item/full-penetrance-allele/">full-penetrance allele</a>) in <i>HTT</i>. A family history is suggestive, but a negative family history should not exclude the diagnosis as information about family members may be missing, or hidden to avoid possible stigmatization.</p><p><b>Clinical features</b></p><ul><li class="half_rhythm"><div>Progressive motor disability featuring involuntary movements (especially chorea) and affecting voluntary movement (e.g., gait, speech, swallowing). Rigidity and bradykinesia may predominate in the later stages of the disease.</div></li><li class="half_rhythm"><div>Psychiatric disturbances including changes in personality and depression</div></li><li class="half_rhythm"><div>Progressive dementia</div></li><li class="half_rhythm"><div>Family history consistent with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> inheritance. Note, however, that family history may be unavailable or inaccurate.</div></li></ul></div><div id="hd-l2.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of Huntington disease-like 2 <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with the above <a href="#hd-l2.Suggestive_Findings">Suggestive Findings</a> and a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> expansion of a CTG <a class="def" href="/books/n/gene/glossary/def-item/trinucleotide-repeat/">trinucleotide repeat</a> in <i>JPH3</i> identified by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1529/table/hd-l2.T.molecular_genetic_testing_used_i/?report=objectonly" target="object" rid-figpopup="fighdl2Tmoleculargenetictestingusedi" rid-ob="figobhdl2Tmoleculargenetictestingusedi">Table 1</a>).</p><p><b>Allele sizes</b></p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Normal alleles.</b> Six to 28 CTG repeats [<a class="bk_pop" href="#hd-l2.REF.holmes.2001.377">Holmes et al 2001</a>]. The diagnosis can be excluded if neither <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> has a repeat length greater than 28 CTG repeats.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Alleles of questionable significance.</b> 29 to 39 CTG repeats; the pathogenicity of alleles in this range is unknown. Repeats in this range could be either of the following:</div><ul><li class="half_rhythm"><div class="half_rhythm"><b>Mutable normal alleles</b> that do not have a phenotypic effect in the individual but are unstable in vertical transmission</div><div class="half_rhythm">Note: (1) A woman age 48 years with an atypical cerebellar disorder (rapid onset following hospitalization for out-of-control diabetes mellitus, little or no progression) had a <i>JPH3</i> CTG repeat length of 33 in one <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>. Her son age 30 years had developed Cogan's syndrome, an autoimmune disease resulting in complete hearing loss, at age 25 years. He complained of tinnitus, occasional lapses of concentration, and difficulty with balance, all associated with the onset of Cogan's syndrome. Examination suggested possible cerebellar involvement. He had a CTG repeat length of 35, suggesting repeat length instability at this range. (2) An individual with molecularly diagnosed Huntington disease coincidentally also had a <i>JPH3</i> allele of 34 CTG repeats [Author, personal observation].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Reduced-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> alleles</b> that result in very late-onset disease and/or a different <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> and/or no occurrence of clinical disease in a normal life span</div></li></ul></li><li class="half_rhythm"><div class="half_rhythm"><b>Full-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> (disease-causing) alleles.</b> 40 CTG repeats or greater. In the presence of a clinical syndrome consistent with HDL2, an <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> with 40 or more CTG repeats is considered diagnostic of HDL2.</div><div class="half_rhythm">Notes: (1) Apparently unaffected individuals with repeat lengths in the pathogenic range may eventually develop the disease. One individual (in a family with a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with clinically, neuropathologically, and molecularly defined HDL2) had an expanded <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> of 44 CTG repeats without clear evidence of clinical HDL2 at age 65 years. It is possible that the effects of a mild stroke several years prior to examination masked signs of HDL2. (2) <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a>-based assays, standard in genetic laboratories, are typically accurate to within ~&#x000b1;1 triplet, complicating interpretation of alleles of borderline length. (3) An allele with 39 CTG repeats has been reported in an individual with an HDL2 <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (4) The longest repeat expansion detected to date is 60 CTG repeats.</div></li></ul><p><b>Molecular genetic testing</b> approaches include <b>targeted testing</b> for the CTG repeat length at the <i>JPH3</i> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a>.</p><div id="hd-l2.T.molecular_genetic_testing_used_i" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Huntington Disease-Like 2</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1529/table/hd-l2.T.molecular_genetic_testing_used_i/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hd-l2.T.molecular_genetic_testing_used_i_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hd-l2.T.molecular_genetic_testing_used_i_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_hd-l2.T.molecular_genetic_testing_used_i_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_hd-l2.T.molecular_genetic_testing_used_i_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_hd-l2.T.molecular_genetic_testing_used_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>JPH3</i></td><td headers="hd_h_hd-l2.T.molecular_genetic_testing_used_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Targeted analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_hd-l2.T.molecular_genetic_testing_used_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%&#x000a0;<sup>4</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="hd-l2.TF.1.1"><p class="no_margin">See <a href="/books/NBK1529/#hd-l2.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="hd-l2.TF.1.2"><p class="no_margin">See <a href="#hd-l2.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="hd-l2.TF.1.3"><p class="no_margin">Detects CTG <a class="def" href="/books/n/gene/glossary/def-item/trinucleotide-repeat/">trinucleotide repeat</a> number. <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a>-based methods can detect expanded alleles including the largest reported <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> of 60 CTG repeats [<a class="bk_pop" href="#hd-l2.REF.anderson.2019a.302">Anderson et al 2019a</a>].</p></div></dd><dt>4. </dt><dd><div id="hd-l2.TF.1.4"><p class="no_margin">The test should detect nearly all expanded alleles [<a class="bk_pop" href="#hd-l2.REF.holmes.2001.377">Holmes et al 2001</a>, <a class="bk_pop" href="#hd-l2.REF.krause.2015.573">Krause et al 2015</a>] However, it is theoretically possible that expanded repeats may not be detected because of a <a class="def" href="/books/n/gene/glossary/def-item/polymorphism/">polymorphism</a> at the primer site or an unusually long repeat. It is recommended that retesting with an alternative primer pair should be attempted in the setting of strong clinical suspicion and apparent homozygosity of <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> length, as a SNP may occasionally interfere with allele detection by <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a>.</p></div></dd></dl></div></div></div></div></div><div id="hd-l2.Clinical_Characteristics"><h2 id="_hd-l2_Clinical_Characteristics_">Clinical Characteristics</h2><div id="hd-l2.Clinical_Description"><h3>Clinical Description</h3><p>Like <a href="/books/n/gene/huntington/">Huntington disease</a> (HD), Huntington disease-like 2 (HDL2) typically presents in midlife with a relentless progressive triad of movement, emotional, and cognitive abnormalities. However, unlike HD, HDL2 has been described exclusively in individuals with African ancestry. More than half of individuals with HDL2 have been reported from South Africa; most of the remaining individuals are from North and South America [<a class="bk_pop" href="#hd-l2.REF.anderson.2017.37">Anderson et al 2017</a>, <a class="bk_pop" href="#hd-l2.REF.walker.2018.10">Walker et al 2018</a>].</p><p>The average age of onset is 41 years (SD=11.1), although the range has been reported to be wide (12-66 years) [<a class="bk_pop" href="#hd-l2.REF.anderson.2017.37">Anderson et al 2017</a>]. The length of the CTG expansion has an inverse correlation with age of onset. Death usually follows ten to 20 years after disease onset [<a class="bk_pop" href="#hd-l2.REF.margolis.2001.373">Margolis et al 2001</a>].</p><p>HDL2 has a broad clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> which is characterized by dementia, with chorea and oculomotor abnormalities as the initial motor symptoms. With longer disease duration, there is progression to a rigid and bradykinetic state with worsening dystonia. HDL2 is indistinguishable from HD in the clinical setting [<a class="bk_pop" href="#hd-l2.REF.anderson.2019a.302">Anderson et al 2019a</a>].</p><p>Chorea is the most common movement abnormality, followed by rigidity, bradykinesia, dysarthria, and dystonia. Hyperreflexia is a late feature of the disease [<a class="bk_pop" href="#hd-l2.REF.anderson.2017.37">Anderson et al 2017</a>]. Oculomotor dysfunction, despite earlier reports [<a class="bk_pop" href="#hd-l2.REF.margolis.2001.373">Margolis et al 2001</a>, <a class="bk_pop" href="#hd-l2.REF.walker.2003a.1527">Walker et al 2003a</a>, <a class="bk_pop" href="#hd-l2.REF.anderson.2017.37">Anderson et al 2017</a>], appears to be as common in HDL2 as in HD, and worsens with longer disease duration [<a class="bk_pop" href="#hd-l2.REF.anderson.2019a.302">Anderson et al 2019a</a>]. As in HD, some patients present with a more rigid, dystonic form of the illness with relatively less chorea.</p><p>Dementia is a universal feature of HDL2 and is similar to the dementia profile seen in HD [<a class="bk_pop" href="#hd-l2.REF.anderson.2017.37">Anderson et al 2017</a>]. Depression, apathy, and irritability are the most common forms of psychiatric disturbance.</p><p><b>Acanthocytosis</b> has been reported in four individuals with HDL2 [<a class="bk_pop" href="#hd-l2.REF.walker.2002.1031">Walker et al 2002</a>, <a class="bk_pop" href="#hd-l2.REF.walker.2003b.1002">Walker et al 2003b</a>]. Subsequent reports have not found acanthocytes in individuals with HDL2. Furthermore, a blinded controlled study did not find acanthocytes in individuals with HDL2 [<a class="bk_pop" href="#hd-l2.REF.anderson.2017.37">Anderson et al 2017</a>]. Therefore, the presence of acanthocytes is unlikely to have clinical or pathogenic relevance in HDL2.</p><p><b>Brain MRI</b> shows the typical features of HD: prominent atrophy of the caudate and cerebral cortex with sparing of the brain stem and cerebellum [<a class="bk_pop" href="#hd-l2.REF.margolis.2001.373">Margolis et al 2001</a>]. A comparison of brain volumes in individuals with HDL2 and HD using semiautomated MRI image analysis confirmed similar cortical and striatal volume loss with greater thalamic atrophy in individuals with HDL2 [<a class="bk_pop" href="#hd-l2.REF.anderson.2019b.101666">Anderson et al 2019b</a>].</p><p><b>Neuropathology.</b> Neuronal loss is most prominent in the striatum and the cerebral cortex. Striatal loss appears limited to medium spiny neurons and occurs in a dorsal-to-ventral gradient as in HD. Intranuclear inclusions that stain with antibodies against polyglutamine, ubiquitin [<a class="bk_pop" href="#hd-l2.REF.margolis.2001.373">Margolis et al 2001</a>, <a class="bk_pop" href="#hd-l2.REF.walker.2002.1031">Walker et al 2002</a>], torsinA [<a class="bk_pop" href="#hd-l2.REF.walker.2002.1031">Walker et al 2002</a>], and TBP have been detected, predominantly in the cortex [<a class="bk_pop" href="#hd-l2.REF.rudnicki.2008.366">Rudnicki et al 2008</a>].</p></div><div id="hd-l2.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>As in HD, longer CTG repeat length correlates with an earlier age of onset in HDL2 [<a class="bk_pop" href="#hd-l2.REF.margolis.2004.670">Margolis et al 2004</a>, <a class="bk_pop" href="#hd-l2.REF.anderson.2017.37">Anderson et al 2017</a>]. It is possible that longer repeat length (~&#x02265;50 CTG repeats) may be associated with a more aggressive course (less chorea; more dystonia, rigidity, and weight loss), observed primarily in the large index family [<a class="bk_pop" href="#hd-l2.REF.margolis.2001.373">Margolis et al 2001</a>], although alternative genetic or environmental factors may be relevant.</p></div><div id="hd-l2.Penetrance"><h3>Penetrance</h3><p>For ethical reasons, only a few unaffected individuals from families with HDL2 have been tested; therefore, the <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> is unknown, though as noted above, one individual with a repeat of 44 triplets did not have evidence of HDL2 at age 65, suggesting the possibility of reduced penetrance in some individuals.</p></div><div id="hd-l2.Anticipation"><h3>Anticipation</h3><p>Limited evidence from the large index <a class="def" href="/books/n/gene/glossary/def-item/pedigree/">pedigree</a> suggests that <a class="def" href="/books/n/gene/glossary/def-item/anticipation/">anticipation</a> may occur [<a class="bk_pop" href="#hd-l2.REF.margolis.2001.373">Margolis et al 2001</a>]. An example of anticipation through paternal inheritance has been described [<a class="bk_pop" href="#hd-l2.REF.greenstein.2007.1416">Greenstein et al 2007</a>]. So far, no large changes in <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> size have been detected in either maternal or paternal transmission. A difference of +3 repeats has been detected in a few sibships, but data are limited.</p></div><div id="hd-l2.Nomenclature"><h3>Nomenclature</h3><p>HDL2 is occasionally (and incorrectly) referred to as HD2.</p></div><div id="hd-l2.Prevalence"><h3>Prevalence</h3><p>Although rare, HDL2 appears to be the most common HD phenocopy in populations with African ancestry. These include France [<a class="bk_pop" href="#hd-l2.REF.mariani.2016.1105">Mariani et al 2016</a>], parts of the Americas [<a class="bk_pop" href="#hd-l2.REF.margolis.2004.670">Margolis et al 2004</a>, <a class="bk_pop" href="#hd-l2.REF.walker.2018.10">Walker et al 2018</a>], and South Africa [<a class="bk_pop" href="#hd-l2.REF.krause.2015.573">Krause et al 2015</a>]. Individuals with HDL2 share a common haplotype which originated in Africa [<a class="bk_pop" href="#hd-l2.REF.krause.2015.573">Krause et al 2015</a>]. The highest number of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals are from South Africa [<a class="bk_pop" href="#hd-l2.REF.anderson.2017.37">Anderson et al 2017</a>]. An analysis of blood samples from individuals with an HD-like <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> referred for HD testing [<a class="bk_pop" href="#hd-l2.REF.krause.2015.573">Krause et al 2015</a>] found that 15% of black South Africans and no white individuals were found to have HDL2, while 62% of whites and 36% of blacks were found to have HD. Therefore, for every two black individuals diagnosed with HD there was approximately one individual diagnosed with HDL2.</p><p>Outside of South Africa, HDL2 has been identified in as few as 1% of individuals with clinically or pathologically defined HD who do not have an <i>HTT</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#hd-l2.REF.rosenblatt.1998.215">Rosenblatt et al 1998</a>, <a class="bk_pop" href="#hd-l2.REF.stevanin.2003.1599">Stevanin et al 2003</a>, <a class="bk_pop" href="#hd-l2.REF.margolis.2004.670">Margolis et al 2004</a>]. In Brazil, where an estimated 44% of the population is of African descent, as many as 10% of individuals with an HD-like disorder may have HDL2 [<a class="bk_pop" href="#hd-l2.REF.rodrigues.2011.419">Rodrigues et al 2011</a>].</p><ul><li class="half_rhythm"><div>Of 300 individuals referred to a large commercial diagnostic laboratory in the United States for HD testing who had tested negative for the HD-causing expansion, two were found to have the HDL2-causing expansion.</div></li><li class="half_rhythm"><div>The first case of HDL2 from Botswana was recently described in a male age 47 years [<a class="bk_pop" href="#hd-l2.REF.ocampo.2018.126">Ocampo et al 2018</a>].</div></li><li class="half_rhythm"><div>Among 74 individuals (60 of French origin) with a variety of movement disorders with and without dementia, 36% of whom had an autosmal dominant inheritance pattern [<a class="bk_pop" href="#hd-l2.REF.stevanin.2002.965">Stevanin et al 2002</a>], only one case of HDL2 was detected, in an individual from North Africa.</div></li><li class="half_rhythm"><div>Among 1600 individuals with movement disorders referred for genetic testing by neurologists in Germany and Austria who did not have an expanded HD <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> (including 147 individuals with a family history of chorea), no HDL2 expansions were found [<a class="bk_pop" href="#hd-l2.REF.bauer.2002.662">Bauer et al 2002</a>].</div></li><li class="half_rhythm"><div>If the cases described above are narrowly defined, the frequency of HDL2 is much higher than indicated. For instance, of four individuals identified by <a class="bk_pop" href="#hd-l2.REF.rosenblatt.1998.215">Rosenblatt et al [1998]</a> with HD-like <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> disorders, two ultimately proved to have HDL2.</div></li><li class="half_rhythm"><div>No cases of HDL2 have yet been detected in Japan, though only a small number of individuals have been tested.</div></li><li class="half_rhythm"><div>HDL2 has been detected in several pedigrees in the Caribbean.</div></li></ul></div></div><div id="hd-l2.Genetically_Related_Allelic_Disord"><h2 id="_hd-l2_Genetically_Related_Allelic_Disord_">Genetically Related (Allelic) Disorders</h2><p>CTG expansions within <i>JPH3</i> have not been associated with other phenotypes. Syndromes arising from deletions including <i>JPH3</i> have been identified [Authors, unpublished communication]; the relevance to HDL2 is uncertain.</p></div><div id="hd-l2.Differential_Diagnosis"><h2 id="_hd-l2_Differential_Diagnosis_">Differential Diagnosis</h2><p>The differential diagnosis of Huntington disease-like 2 (HDL2) is the same as for <a href="/books/n/gene/huntington/">Huntington disease</a> (HD), and is based on the co-occurrence of: (1) movement abnormalities (chorea, dystonia, and/or parkinsonism) reflecting basal ganglia dysfunction, dementia, and psychiatric disturbances; and (2) <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> inheritance.</p><p>The most obvious diagnosis to exclude is HD itself. HD and other disorders to be considered are summarized in <a class="figpopup" href="/books/NBK1529/table/hd-l2.T.inherited_conditions_to_consider/?report=objectonly" target="object" rid-figpopup="fighdl2Tinheritedconditionstoconsider" rid-ob="figobhdl2Tinheritedconditionstoconsider">Table 2</a>.</p><div id="hd-l2.T.inherited_conditions_to_consider" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Inherited Conditions to Consider in the Differential Diagnosis of Huntington Disease-Like 2 (HDL2)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1529/table/hd-l2.T.inherited_conditions_to_consider/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hd-l2.T.inherited_conditions_to_consider_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_1" style="text-align:left;vertical-align:middle;">Differential<br />Diagnosis<br />Disorder</th><th id="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_2" style="text-align:left;vertical-align:middle;">Gene(s)</th><th id="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_3" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Clinical Features of Differential Diagnosis Disorder</th></tr><tr><th headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4" id="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Overlapping w/HDL2</th><th headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4" id="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distinguishing from HDL2</th></tr></thead><tbody><tr><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/huntington/">Huntington disease</a></td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HTT</i></td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Clinically indistinguishable from HDL2</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Possibly greater thalamic volume than in HDL2 (unlikely to be diagnostically useful in single cases)</td></tr><tr><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/neuroferritin/">Neuroferritinopathy</a></td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>FTL</i></td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Chorea</div></li><li class="half_rhythm"><div>Dystonia</div></li><li class="half_rhythm"><div>Parkinsonism</div></li></ul>
</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dementia rare</td></tr><tr><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/drpla/">Dentatorubral-pallidoluysian atrophy</a></td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ATN1</i></td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Progressive movement disorder &#x00026; dementia</div></li><li class="half_rhythm"><div>Psychiatric disturbances</div></li></ul>
</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Prominent ataxia &#x00026; myoclonus</div></li><li class="half_rhythm"><div>More common in Japan</div></li></ul>
</td></tr><tr><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/chac/">Chorea-acanthocytosis</a></td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>VPS13A</i></td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Progressive movement disorder</div></li><li class="half_rhythm"><div>Progressive cognitive &#x00026; behavior changes</div></li></ul>
</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Myopathy</div></li><li class="half_rhythm"><div>&#x02191; serum CK</div></li><li class="half_rhythm"><div>Acanthocytosis</div></li><li class="half_rhythm"><div>Seizures common</div></li><li class="half_rhythm"><div>Mean onset age ~30 yrs</div></li></ul>
</td></tr><tr><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Benign hereditary chorea<br />(OMIM <a href="http://www.omim.org/entry/118700" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">118700</a>)</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>NKX2-1</i></td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Chorea</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Usually childhood onset</div></li><li class="half_rhythm"><div>Chorea is non-progressive.</div></li><li class="half_rhythm"><div>No dementia</div></li></ul>
</td></tr><tr><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/sca2/">Spinocerebellar ataxia type 2</a></td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ATXN2</i></td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Chorea</div></li><li class="half_rhythm"><div>Parkinsonism</div></li><li class="half_rhythm"><div>Dystonia</div></li><li class="half_rhythm"><div>Oculomotor dysfunction</div></li></ul>
</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cerebellar ataxia is the prominent movement disorder.</td></tr><tr><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/sca3/">Spinocerebellar ataxia type 3</a></td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ATXN3</i></td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Chorea (rare)</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cerebellar ataxia is the prominent movement disorder.</td></tr><tr><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/sca17/">Spinocerebellar ataxia type 17</a></td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>TBP</i></td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Chorea</div></li><li class="half_rhythm"><div>Dementia</div></li><li class="half_rhythm"><div>Psychiatric disturbances</div></li></ul>
</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cerebellar ataxia is typical but not uniformly present.</td></tr><tr><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Familial Creutzfeld-Jakob disease (fCJD; see <a href="/books/n/gene/prion/">Genetic Prion Diseases</a>)</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PRNP</i></td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Typically late onset</div></li><li class="half_rhythm"><div>Progressive dementia</div></li><li class="half_rhythm"><div>Movement disorders</div></li><li class="half_rhythm"><div>Behavior changes &#x00026; psychiatric symptoms</div></li></ul>
</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Progresses more rapidly than HDL2</div></li><li class="half_rhythm"><div>Prominent myoclonus</div></li></ul>
</td></tr><tr><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/wilson/">Wilson disease</a></td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ATP7B</i></td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Movement disorders</div></li><li class="half_rhythm"><div>Psychiatric disorders</div></li></ul>
</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Liver disease</div></li><li class="half_rhythm"><div>Kayser-Fleischer rings</div></li><li class="half_rhythm"><div>Copper abnormalities</div></li><li class="half_rhythm"><div>Exclusion is essential since Wilson disease is treatable.</div></li></ul>
</td></tr><tr><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/ncl/">Neuronal ceroid-lipofuscinoses</a></td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;10 genes&#x000a0;<sup>1</sup></td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR<br />AD</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Movement disorder</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Usually AR w/childhood onset, rarely AD w/adult onset</td></tr><tr><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/pkan/">Pantothenate kinase-associated neurodegeneration</a></td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PANK2</i></td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Parkinsonism</div></li><li class="half_rhythm"><div>Dystonia</div></li><li class="half_rhythm"><div>Dementia</div></li></ul>
</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Childhood onset w/early falls &#x00026;visual disturbances</div></li><li class="half_rhythm"><div>MRI features</div></li></ul>
</td></tr><tr><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/bgc/">Primary familial brain calcification</a> (<a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> <a class="def" href="/books/n/gene/glossary/def-item/idiopathic/">idiopathic</a> basal ganglia calcification)</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PDGFB</i><br /><i>PDGFRB</i><br /><i>SLC20A2</i><br /><i>XPR1</i></td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Parkinsonism</div></li><li class="half_rhythm"><div>Chorea</div></li><li class="half_rhythm"><div>Dystonia</div></li></ul>
</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">MRI features</td></tr><tr><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mitochondrial disorders<br />(see <a href="/books/n/gene/mt-overview/">Mitochondrial Disorders Overview</a>)</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 2</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR<br />AD<br />mt</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Chorea</div></li><li class="half_rhythm"><div>Cognitive impairment</div></li></ul>
</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>MRI necrosis</div></li><li class="half_rhythm"><div>Pyruvate/lactate abnormalities</div></li></ul>
</td></tr><tr><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/mcleod/">McLeod neuroacanthocytosis syndrome</a></td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>XK</i></td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XL</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Cognitive impairment</div></li><li class="half_rhythm"><div>Psychiatric symptoms</div></li><li class="half_rhythm"><div>Chorea</div></li></ul>
</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Acanthocytosis, compensated hemolysis, &#x00026; McLeod blood group <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a></div></li><li class="half_rhythm"><div>Seizures</div></li><li class="half_rhythm"><div>Peripheral neuropathy</div></li><li class="half_rhythm"><div>Hyporeflexia</div></li><li class="half_rhythm"><div>Cardiomyopathy</div></li><li class="half_rhythm"><div>Hepatosplenomegaly</div></li></ul>
</td></tr><tr><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Parkinsonian conditions (see <a href="/books/n/gene/parkinson-overview/">Parkinson Disease</a>)</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 3</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD<br />AR<br />XL&#x000a0;<sup>4</sup></td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Parkinsonism</div></li><li class="half_rhythm"><div>Dystonia</div></li><li class="half_rhythm"><div>Family history</div></li></ul>
</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Striatal atrophy early</div></li><li class="half_rhythm"><div>No chorea</div></li></ul>
</td></tr><tr><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Progressive supranuclear palsy; corticobasal ganglia degeneration; frontotemporal dementia w/parkinsonism-17 (see <a href="/books/n/gene/ftdp-17/"><i>MAPT</i>-Related Disorders</a>)</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>MAPT</i></td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Late-onset</div></li><li class="half_rhythm"><div>Progressive movement disorders, dementia, &#x00026; behavior changes</div></li><li class="half_rhythm"><div>Psychiatric disturbances</div></li></ul>
</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No chorea</td></tr><tr><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Frontotemporal dementia &#x00026;/or amyotrophic lateral sclerosis<br />(OMIM <a href="https://omim.org/entry/105550" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">105550</a>)</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>C9orf72</i></td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Movement disorders</div></li><li class="half_rhythm"><div>Dementia</div></li><li class="half_rhythm"><div>Psychiatric disturbances</div></li></ul>
</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Myoclonus, tremor, torticollis</td></tr><tr><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Huntington disease-like 1<br />(OMIM <a href="http://www.omim.org/entry/603218" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">603218</a>)&#x000a0;<sup>5</sup></td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PRNP</i></td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Range of clinical features that overlap w/HD</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Early-onset, slowly progressive</td></tr><tr><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hereditary cerebellar ataxia (see <a href="/books/n/gene/ataxias/">Hereditary Ataxia Overview</a>)</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Many</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD<br />AR<br />XL</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Movement disorder</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hereditary cerebellar ataxia associated w/prominent cerebellar &#x00026; long tract signs</td></tr><tr><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Early-onset <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> Alzheimer disease (see <a href="https://www.ncbi.nlm.nih.gov/books/NBK1161/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Alzheimer Disease Overview</a>)</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>APP</i><br /><i>PSEN1</i><br /><i>PSEN2</i></td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dementia</td><td headers="hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_1_4 hd_h_hd-l2.T.inherited_conditions_to_consider_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No movement abnormalities</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>; mt = mitochondrial; XL = <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a></p></div></dd><dt>1. </dt><dd><div id="hd-l2.TF.2.1"><p class="no_margin">See <a href="https://omim.org/phenotypicSeries/PS256730" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Phenotypic Series: Ceroid lipofuscinoses</a> for genes associated with this <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in OMIM.</p></div></dd><dt>2. </dt><dd><div id="hd-l2.TF.2.2"><p class="no_margin">Mitochondrial disorders may be caused by defects of nuclear DNA or mtDNA (see <a href="/books/n/gene/mt-overview/">Mitochondrial Disorders Overview</a>).</p></div></dd><dt>3. </dt><dd><div id="hd-l2.TF.2.3"><p class="no_margin">See <a href="http://omim.org/phenotypicSeries/PS168600" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Parkinson disease: Phenotypic Series</a> to view genes associated with this <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in OMIM.</p></div></dd><dt>4. </dt><dd><div id="hd-l2.TF.2.4"><p class="no_margin">Mendelian (monogenic) forms of Parkinson disease are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>, <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>, or, rarely, <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner. For Mendelian forms of Parkinson disease, <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> depends on the <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>. In contrast, most Parkinson disease is thought to be non-Mendelian and to result from the effects of multiple genes as well as environmental risk factors.</p></div></dd><dt>5. </dt><dd><div id="hd-l2.TF.2.5"><p class="no_margin">HDL1 is caused by a specific <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (8 extra octapeptide repeats) in the prion protein <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>, <i>PRNP</i>, on <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 20p. Similar pathogenic variants at this <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> also result in other forms of prion disease, such as <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> Creutzfeldt-Jakob disease (see <a href="/books/n/gene/prion/">Genetic Prion Diseases</a>).</p></div></dd></dl></div></div></div><p>Nonfamilial disorders that may present like HDL2 include: tardive dyskinesia (common), Sydenham's chorea, systemic lupus erythematosus (SLE), neurosyphilis, hyperglycemia, acquired forms of Creutzfeld-Jakob disease, pregnancy, multisystem atrophy, and thyroid disease.</p><p>HDL2-like symptoms can also arise from drugs including: antipsychotics, anticonvulsants, oral contraceptives, lithium, and stimulants.</p></div><div id="hd-l2.Management"><h2 id="_hd-l2_Management_">Management</h2><div id="hd-l2.Evaluations_Following_Initial_Diag"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease in an individual diagnosed with Huntington disease-like 2 (HDL2), the following evaluations (if not performed as part of the evaluation that led to the diagnosis) are recommended:</p><ul><li class="half_rhythm"><div>Neuroimaging studies to exclude other lesions, such as subdural hematomas secondary to falls, which may be contributing to signs or symptoms</div></li><li class="half_rhythm"><div>Standardized rating assessments to track progress, such as the Unified Huntington's Disease Rating Scale (UHDRS) or Quantitated Neurological Examination (QNE) for motor abnormalities and the Mini-Mental State Examination (MMSE) or Montreal Cognitive Assessment (MoCA) for cognition</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="hd-l2.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Treatment is symptomatic and based on the treatment for HD and other neurodegenerative disorders.</p><ul><li class="half_rhythm"><div>Pharmacologic agents may suppress abnormal movements. The most common choices are tetrabenazine and its derivatives; consider also low-dose neuroleptic agents such as fluphenazine or haloperidol.</div></li><li class="half_rhythm"><div>Tremor in one individual was suppressed with clonazepam. However, clonazepam, levodopa/carbidopa, anticholinergics, and typical and atypical neuroleptics were not found helpful in treating the abnormal movements of other <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</div></li><li class="half_rhythm"><div>Based on experience with <a href="/books/n/gene/huntington/">Huntington disease</a>, antidepressants, antipsychotics, mood stabilizers (lithium, valproic acid, carbamazepine, and lamotrigine), electroconvulsive therapy, and occasionally stimulants may be effective in treating the psychiatric manifestations of HDL2.</div></li><li class="half_rhythm"><div>In the only report specifically related to HDL2, depression partially responded to sertraline in one individual and to nortriptyline in another individual [<a class="bk_pop" href="#hd-l2.REF.walker.2003b.1002">Walker et al 2003b</a>].</div></li><li class="half_rhythm"><div>The <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual, other family members, and care providers should be educated regarding the likely course of the disease. Assurance that cognitive decline, depression, apathy, and irritability are manifestations of the disease rather than the "fault" of the individual can decrease stress and guilt.</div></li><li class="half_rhythm"><div>Environmental interventions (establishing regular schedules, easing of expectations to maintain the family finances, encouraging the use of lists to assist with memory) may help.</div></li><li class="half_rhythm"><div>Implementation of safety precautions, particularly at home: removal of loose rugs and clutter, minimizing or elimination of the need for stairs, careful assessment of competency for driving. Food preparation may need to be altered to prevent choking.</div></li><li class="half_rhythm"><div>Planning for financial matters (e.g., assigning power of attorney)</div></li><li class="half_rhythm"><div>Families often need help in obtaining social services (see <a href="#hd-l2.Resources">Resources</a>).</div></li></ul></div><div id="hd-l2.Surveillance"><h3>Surveillance</h3><p>Nutrition and swallowing should be monitored. Feeding changes should be implemented when necessary to minimize the risk of aspiration.</p><p>Gait should be monitored, with consultation as needed from physical therapists to provide the most appropriate strategies or devices to minimize falls.</p><p>Driving safety should be monitored, with consideration of formal driving safety evaluations if safety is uncertain.</p><p>Monitor mood and irritability so that measures to decrease behavior abnormalities, distress, and the risk for suicide may be implemented.</p></div><div id="hd-l2.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Any agents that increase ataxia should be used with caution.</p><p>Individuals with HDL2, like others with neurodegenerative disorders, are vulnerable to delirium from medical illnesses and medicines, especially polypharmacy.</p></div><div id="hd-l2.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#hd-l2.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="hd-l2.Pregnancy_Management"><h3>Pregnancy Management</h3><p>There is no specific information available about disease management during pregnancy. Prudence suggests close attention to prevention of falls and monitoring for swallowing difficulties. Medications should be reviewed to assess their safety during pregnancy. See <a href="http://www.mothertobaby.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MotherToBaby</a> for further information on medication use during pregnancy.</p></div><div id="hd-l2.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="hd-l2.Genetic_Counseling"><h2 id="_hd-l2_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="hd-l2.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Huntington disease-like 2 (HDL2) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p><p>Note: HDL2 and <a href="/books/n/gene/huntington/">Huntington disease</a> cannot be clinically distinguished [<a class="bk_pop" href="#hd-l2.REF.anderson.2019a.302">Anderson et al 2019a</a>], complicating <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> in families in which a diagnosis has not been confirmed with <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a href="#hd-l2.Diagnosis">Diagnosis</a>); this distinction is critical for predictive testing and may be of relevance if treatments specific for Huntington disease emerge from ongoing clinical trials.</p></div><div id="hd-l2.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Most individuals with HDL2 have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent.</div></li><li class="half_rhythm"><div><i>De novo</i> pathogenic variants have not been reported as a cause of HDL2, but information about repeat length transmission is lacking in most families. It is theoretically possible that a repeat expansion of a mutable normal <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> / <a class="def" href="/books/n/gene/glossary/def-item/reduced-penetrance-allele/">reduced-penetrance allele</a> into the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> range may occur, as it does in Huntington disease; however, such an event has not been documented to date.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> to asymptomatic parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> who appears to represent a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case (i.e., a single occurrence in a family). Note: Testing for the expansion in the absence of symptoms of the disease is predictive testing and <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a>, both before and after testing, is essential.</div></li><li class="half_rhythm"><div>Although most individuals diagnosed with HDL2 have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent, the family history may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or late onset of the disease in the affected parent.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to the sibs of the proband depends on the genetic status of the proband's parents:</p><ul><li class="half_rhythm"><div class="half_rhythm">If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> and/or has a <i>JPH3</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> with 40 CTG repeats or greater, the risk to the sibs is 50%.</div><div class="half_rhythm">Theoretically, an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent with a repeat length just at the disease threshold could transmit an expanded <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> to one sib and an unexpanded allele to another sib; such a case has not yet been detected.</div></li><li class="half_rhythm"><div class="half_rhythm">If a parent has a high normal-length <i>JPH3</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> (i.e., close to 40 repeats), the risk of the offspring inheriting an HDL2-causing allele is currently uncertain, but would be greater than 0%. If one sib has inherited an expanded allele from a parent with a high normal-length allele, the risk would be predicted to be significant, though not yet quantifiable.</div></li><li class="half_rhythm"><div class="half_rhythm">A sib who inherits a <i>JPH3</i> <a class="def" href="/books/n/gene/glossary/def-item/reduced-penetrance-allele/">reduced-penetrance allele</a> may or may not develop symptoms of HDL2.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each child of an individual with HDL2 has a 50% chance of inheriting the HDL2-causing <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>.</div></li><li class="half_rhythm"><div>Offspring who inherit a <i>JPH3</i> <a class="def" href="/books/n/gene/glossary/def-item/reduced-penetrance-allele/">reduced-penetrance allele</a> may or may not develop symptoms of HDL2.</div></li></ul><p><b>Other family members</b></p><ul><li class="half_rhythm"><div>The risk to other family members depends on the genetic status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> and/or <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an HDL2-causing expansion, his or her other family members are at potential risk depending on their relatedness.</div></li><li class="half_rhythm"><div>Offspring of an asymptomatic individual <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> of fewer than 40 repeats may be at risk for HDL2 because of the potential for expansion during vertical transmission. This is probably more likely if the allele of the asymptomatic individual is close to 40 repeats in length.</div></li></ul></div><div id="hd-l2.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> expansion.</b> When neither parent has an HDL2-causing expansion (&#x02265;40 CTG triplets) or an <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> of questionable significance (29-39 triplets), explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) or undisclosed adoption may need to be explored, as the information could have implications for other potentially at-risk family members.</p><p><b>Testing of at-risk asymptomatic adults (predictive testing).</b> Testing of asymptomatic adults at risk for HDL2 is possible. When testing at-risk individuals for HDL2, an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member should be tested first to confirm the molecular diagnosis of HDL2 in the family.</p><p>Whether an asymptomatic adult will develop HDL2 can be predicted by the presence of a repeat expansion at the HDL2 <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a>, although this prediction must be qualified by the fact that the correlation between repeat length and disease has been examined in relatively few individuals. In particular, the <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of repeat lengths near the disease threshold and the association between age of onset and repeat length have not been well established. As additional persons with HDL2 are reported, the reliability of clinical predictions based on the length of the HDL2-causing expansion will increase.</p><p>At-risk asymptomatic adult family members may seek testing in order to make personal decisions regarding reproduction, financial matters, and career planning. Others may have different motivations including simply the "need to know." Testing of asymptomatic at-risk adult family members involves pre-test counseling in which the motives for requesting the test, the individual's knowledge of HDL2, the possible impact of positive and negative test results, and neurologic status are discussed. Those seeking testing should be counseled about possible problems that they may encounter with regard to health, life, and disability insurance coverage, employment and educational discrimination, and changes in social and family interaction. Other issues to consider are implications for the at-risk status of other family members, and the limited information available about HDL2. Informed consent should be procured, and records kept confidential. Individuals with a positive test result need arrangements for long-term follow up and evaluations.</p><p>The best model for HDL2 predictive testing is <a href="/books/n/gene/huntington/">Huntington disease</a> predictive testing. Prudence suggests following the same genetic testing guidelines used for Huntington disease, including counseling prior to testing, a confidant to serve as a social support, and availability of counseling following the disclosure of genetic results.</p><p><b>Predictive testing in minors (i.e., testing of asymptomatic at-risk individuals age &#x0003c;18 years)</b></p><ul><li class="half_rhythm"><div>For asymptomatic minors at risk for adult-onset conditions for which early treatment would have no beneficial effect on disease morbidity and mortality, predictive genetic testing is considered inappropriate, primarily because it negates the autonomy of the child with no compelling benefit. Further, concern exists regarding the potential unhealthy adverse effects that such information may have on family dynamics, the risk of discrimination and stigmatization in the future, and the anxiety that such information may cause. This recommendation may change if effective disease-modifying treatments are developed.</div></li><li class="half_rhythm"><div>For more information, see the National Society of Genetic Counselors <a href="https://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">position statement</a> on genetic testing of minors for adult-onset conditions and the American Academy of Pediatrics and American College of Medical Genetics and Genomics <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">policy statement</a>: ethical and policy issues in genetic testing and screening of children.</div></li></ul><p>In a family with an established diagnosis of HDL2, it is appropriate to consider testing of symptomatic individuals regardless of age.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals following appropriate ethical guidelines for storage and access to DNA and identifying information.</p></div><div id="hd-l2.Prenatal_Testing_and_Preimplantati"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p><b>For fetuses at 50% risk.</b> If the presence of an HDL2-causing <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> has been confirmed in the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent or in an affected relative of the at-risk parent, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> (PGD) are possible.</p><p>A PGD exclusion protocol may be an option for testing of the embryo of couples in an at-risk family who do not wish to undergo presymptomatic testing for the HDL2-causing <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> themselves. While there is no known example of PGD applied to HDL2, the concepts and procedures would be nearly identical to those of HD.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing when the testing is being considered for the purpose of pregnancy termination or for early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="hd-l2.Resources"><h2 id="_hd-l2_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Hereditary Disease Foundation</b></div><div>3960 Broadway</div><div>6th Floor</div><div>New York NY 10032</div><div><b>Phone:</b> 212-928-2121</div><div><b>Fax:</b> 212-928-2172</div><div><b>Email:</b> cures@hdfoundation.org</div><div><a href="http://www.hdfoundation.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.hdfoundation.org</a></div></li><li class="half_rhythm"><div><b>Huntington Society of Canada</b></div><div>151 Frederick Street</div><div>Suite 400</div><div>Kitchener Ontario N2H 2M2</div><div>Canada</div><div><b>Phone:</b> 800-998-7398 (toll-free); 519-749-7063</div><div><b>Fax:</b> 519-749-8965</div><div><b>Email:</b> info@huntingtonsociety.ca</div><div><a href="http://www.huntingtonsociety.ca" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.huntingtonsociety.ca</a></div></li><li class="half_rhythm"><div><b>Huntington&#x02019;s Disease Africa</b></div><div><b>Phone:</b> 254746734559</div><div><b>Email:</b> info@hd-africa.org</div><div><a href="https://hd-africa.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.hd-africa.org</a></div></li><li class="half_rhythm"><div><b>Huntingtons Association of South Africa (HASA)</b></div><div>South Africa</div><div><a href="https://huntingtons.org.za/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.huntingtons.org.za</a></div></li><li class="half_rhythm"><div><b>Huntington's Disease Society of America (HDSA)</b></div><div>505 Eighth Avenue</div><div>Suite 902</div><div>New York NY 10018</div><div><b>Phone:</b> 800-345-4372 (toll-free); 212-242-1968</div><div><b>Fax:</b> 212-239-3430</div><div><b>Email:</b> hdsainfo@hdsa.org</div><div><a href="http://www.hdsa.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.hdsa.org</a></div></li><li class="half_rhythm"><div><b>International Huntington Association</b></div><div>Netherlands</div><div><b>Email:</b> svein@iha-huntington.org</div><div><a href="http://huntington-disease.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.huntington-disease.org</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="https://ghr.nlm.nih.gov/condition/huntington-disease-like-syndrome" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Huntington disease</a></div></li></ul></div><div id="hd-l2.Molecular_Genetics"><h2 id="_hd-l2_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="hd-l2.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Huntington Disease-Like 2: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1529/table/hd-l2.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hd-l2.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_hd-l2.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_hd-l2.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_hd-l2.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_hd-l2.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_hd-l2.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_hd-l2.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_hd-l2.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/57338" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>JPH3</i></a></td><td headers="hd_b_hd-l2.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=57338" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">16q24<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_hd-l2.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q8WXH2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Junctophilin-3</a></td><td headers="hd_b_hd-l2.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/JPH3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">JPH3 database</a></td><td headers="hd_b_hd-l2.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=JPH3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">JPH3</a></td><td headers="hd_b_hd-l2.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=JPH3[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">JPH3</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="hd-l2.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="hd-l2.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Huntington Disease-Like 2 (<a href="/omim/605268,606438" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1529/table/hd-l2.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hd-l2.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/605268" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">605268</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">JUNCTOPHILIN 3; JPH3</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/606438" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">606438</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HUNTINGTON DISEASE-LIKE 2; HDL2</td></tr></tbody></table></div></div><div id="hd-l2.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p><b>Introduction.</b> HDL2 is caused by a CTG expansion on <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 16q24.2, which is located on the sense strand in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 2A of <i>JPH3</i>. The primary <i>JPH3</i> transcript does not contain exon 2A with the repeat [<a class="bk_pop" href="#hd-l2.REF.holmes.2001.377">Holmes et al 2001</a>].</p><p>The junctophilin-3 protein, which is primarily expressed in the brain, appears to help establish the junctional complex between the cytoplasmic membrane and the endoplasmic reticulum (ER). This may serve to link voltage-gated calcium channels with calcium release channels in the ER [<a class="bk_pop" href="#hd-l2.REF.nishi.2000.920">Nishi et al 2000</a>, <a class="bk_pop" href="#hd-l2.REF.takeshima.2000.11">Takeshima et al 2000</a>, <a class="bk_pop" href="#hd-l2.REF.ito.2001.1059">Ito et al 2001</a>]. Other possible functions of the protein have not been systematically investigated; however the closely related protein junctophilin-2 may function as a transcriptional regulator factor [<a class="bk_pop" href="#hd-l2.REF.guo.2018.362">Guo et al 2018</a>].</p><p>A <i>JPH</i>3 transcript containing <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 1 and exon 2A is also expressed. Because alternate splice acceptor sites occur between exon 1 and exon 2A in this transcript, the repeat may exist in three alternate reading frames, in which it could encode polyalanine or polyleucine, or fall in the 3' untranslated region.</p><p>The expression pattern and function of the <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 1 &#x02013; exon 2A transcript variants are not known. This short transcript contains the plasma membrane recognition motif, but not the ER insertion <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>, present in the full-length transcript.</p><p>In the antisense strand, the repeat consists of a CAG repeat predicted to encode a polyglutamine tract within a cryptic unnamed <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>. The antisense gene does appear to be transcribed, though whether it is transcribed when the repeat is expanded, and whether the transcript is translated, remains unknown [<a class="bk_pop" href="#hd-l2.REF.wilburn.2011.427">Wilburn et al 2011</a>, <a class="bk_pop" href="#hd-l2.REF.seixas.2012.245">Seixas et al 2012</a>].</p><p><b>Mechanism of disease causation.</b> Although associated with CTG expansion, the molecular pathogenesis of HDL2 remains unknown. Available evidence suggests at least three non-mutually exclusive mechanisms:</p><ul><li class="half_rhythm"><div>Loss of function by sequestration of <i>JPH3</i> RNA carrying the expanded repeat, with subsequent loss of protein expression [<a class="bk_pop" href="#hd-l2.REF.seixas.2012.245">Seixas et al 2012</a>]</div></li><li class="half_rhythm"><div>Gain of function from toxic properties of <i>JPH3</i> transcripts containing an expanded repeat [<a class="bk_pop" href="#hd-l2.REF.rudnicki.2007.272">Rudnicki et al 2007</a>]</div></li><li class="half_rhythm"><div>Toxic gain of function from the expression of protein containing an expanded polyamino acid tract from either sense or antisense strands [<a class="bk_pop" href="#hd-l2.REF.wilburn.2011.427">Wilburn et al 2011</a>]</div></li></ul><p><b><i>JPH3</i>-specific laboratory technical considerations.</b> Laboratory testing is similar to that performed for other repeat expansion diseases. As such, unknown variations in sequence that affect <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> efficiency, or very long repeat lengths, could lead to a failure to detect a repeat expansion. Therefore, detection of a single <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> should not automatically lead to the conclusion that an individual is <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for a repeat of that length; repeat length in other family members, or additional testing, may be necessary to prove that a long expansion is not present.</p></div></div><div id="hd-l2.References"><h2 id="_hd-l2_References_">References</h2><div id="hd-l2.Published_Guidelines__Consensus_St"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="hd-l2.REF1">Committee on Bioethics, Committee on Genetics, and American College of Medical Genetics and Genomics Social, Ethical, Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. Available <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2013. Accessed 6-20-19. [<a href="/pubmed/23428972" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23428972</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hd-l2.REF2">National Society of Genetic Counselors. Position statement on genetic testing of minors for adult-onset disorders. Available <a href="http://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2018. Accessed 6-20-19.</div></li></ul></div><div id="hd-l2.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="hd-l2.REF.anderson.2017.37">Anderson DG, Walker RH, Connor M, Carr J, Margolis RL, Krause A. A systematic review of the Huntington disease-like 2 phenotype. <span><span class="ref-journal">J Huntingtons Dis. </span>2017;<span class="ref-vol">6</span>:37–46.</span> [<a href="/pubmed/28339400" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28339400</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hd-l2.REF.anderson.2019a.302">Anderson DG, Ferreira-Correia A, Rodrigues FB, Aziz NA, Carr J, Wild EJ, Margolis RL, Krause A. Comparison of the Huntington's disease like 2 and Huntington&#x02019;s disease clinical phenotypes. <span><span class="ref-journal">Mov Disord Clin Pract. </span>2019a;<span class="ref-vol">6</span>:302–11.</span> [<a href="/pmc/articles/PMC6476590/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6476590</span></a>] [<a href="/pubmed/31061838" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31061838</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hd-l2.REF.anderson.2019b.101666">Anderson DG, Haagensen M, Ferreira-Correia A, Pierson R, Carr J, Krause A, Margolis RL. Emerging differences between Huntington&#x02018;s disease-like 2 and Huntington&#x02019;s disease: A comparison using MRI brain volumetry. <span><span class="ref-journal">Neuroimage Clin. </span>2019b;<span class="ref-vol">21</span>:101666.</span> [<a href="/pmc/articles/PMC6350216/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6350216</span></a>] [<a href="/pubmed/30682531" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30682531</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hd-l2.REF.bauer.2002.662">Bauer I, Gencik M, Laccone F, Peters H, Weber BH, Feder EH, Weirich H, Morris-Rosendahl DJ, Rolfs A, Gencikova A, Bauer P, Wenning GK, Epplen JT, Holmes SE, Margolis RL, Ross CA, Riess O. Trinucleotide repeat expansions in the junctophilin-3 gene are not found in Caucasian patients with a Huntington's disease-like phenotype. <span><span class="ref-journal">Ann Neurol. </span>2002;<span class="ref-vol">51</span>:662.</span> [<a href="/pubmed/12112122" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12112122</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hd-l2.REF.greenstein.2007.1416">Greenstein PE, Vonsattel JP, Margolis RL, Joseph JT. Huntington's disease like-2 neuropathology. <span><span class="ref-journal">Mov Disord. </span>2007;<span class="ref-vol">22</span>:1416–23.</span> [<a href="/pubmed/17516481" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17516481</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hd-l2.REF.guo.2018.362">Guo A, Wang Y, Chen B, Wang Y, Yuan J, Zhang L, Hall D, Wu J, Shi Y, Zhu Q, Chen C, Thiel WH, Zhan X, Weiss RM, Zhan F, Musselman CA, Pufall M, Zhu W, Au KF, Hong J, Anderson ME, Grueter CE, Song LS. E-C coupling structural protein junctophilin-2 encodes a stress-adaptive transcription regulator. <span><span class="ref-journal">Science. </span>2018:362.</span> [<a href="/pmc/articles/PMC6336677/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6336677</span></a>] [<a href="/pubmed/30409805" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30409805</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hd-l2.REF.holmes.2001.377">Holmes SE, O'Hearn E, Rosenblatt A, Callahan C, Hwang HS, Ingersoll-Ashworth RG, Fleisher A, Stevanin G, Brice A, Potter NT, Ross CA, Margolis RL. A repeat expansion in the gene encoding junctophilin-3 is associated with Huntington disease-like 2. <span><span class="ref-journal">Nat Genet. </span>2001;<span class="ref-vol">29</span>:377–8.</span> [<a href="/pubmed/11694876" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11694876</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hd-l2.REF.ito.2001.1059">Ito K, Komazaki S, Sasamoto K, Yoshida M, Nishi M, Kitamura K, Takeshima H. Deficiency of triad junction and contraction in mutant skeletal muscle lacking junctophilin type 1. <span><span class="ref-journal">J Cell Biol. </span>2001;<span class="ref-vol">154</span>:1059–67.</span> [<a href="/pmc/articles/PMC2196186/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2196186</span></a>] [<a href="/pubmed/11535622" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11535622</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hd-l2.REF.krause.2015.573">Krause A, Mitchell C, Essop F, Tager S, Temlett J, Stevanin G, Ross C, Rudnicki D, Margolis R. Junctophilin 3 (JPH3) expansion mutations causing Huntington disease like 2 (HDL2) are common in South African patients with African ancestry and a Huntington disease phenotype. <span><span class="ref-journal">Am J Med Genet B Neuropsychiatr Genet. </span>2015;<span class="ref-vol">168</span>:573–85.</span> [<a href="/pmc/articles/PMC4565761/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4565761</span></a>] [<a href="/pubmed/26079385" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26079385</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hd-l2.REF.margolis.2004.670">Margolis RL, Holmes SE, Rosenblatt A, Gourley L, O'Hearn E, Ross CA, Seltzer WK, Walker RH, Ashizawa T, Rasmussen A, Hayden M, Almqvist EW, Harris J, Fahn S, MacDonald ME, Mysore J, Shimohata T, Tsuji S, Potter N, Nakaso K, Adachi Y, Nakashima K, Bird T, Krause A, Greenstein P. Huntington's disease-like 2 (HDL2) in North America and Japan. <span><span class="ref-journal">Ann Neurol. </span>2004;<span class="ref-vol">56</span>:670–4.</span> [<a href="/pubmed/15468075" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15468075</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hd-l2.REF.margolis.2001.373">Margolis RL, O'Hearn E, Rosenblatt A, Willour V, Holmes SE, Franz ML, Callahan C, Hwang HS, Troncoso JC, Ross CA. A disorder similar to Huntington's disease is associated with a novel CAG repeat expansion. <span><span class="ref-journal">Ann Neurol. </span>2001;<span class="ref-vol">50</span>:373–80.</span> [<a href="/pubmed/11558794" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11558794</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hd-l2.REF.mariani.2016.1105">Mariani LL, Tesson C, Charles P, Cazeneuve C, Hahn V, Youssov K, Freeman L, Grabli D, Roze E, No&#x000eb;l S, Peuvion JN, Bachoud-Levi AC, Brice A, Stevanin G, Durr A. Expanding the spectrum of genes involved in Huntington disease using a combined clinical and genetic approach. <span><span class="ref-journal">JAMA Neurol. </span>2016;<span class="ref-vol">73</span>:1105–14.</span> [<a href="/pubmed/27400454" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27400454</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hd-l2.REF.nishi.2000.920">Nishi M, Mizushima A, Nakagawara K, Takeshima H. Characterization of human junctophilin subtype genes. <span><span class="ref-journal">Biochem Biophys Res Commun. </span>2000;<span class="ref-vol">273</span>:920–7.</span> [<a href="/pubmed/10891348" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10891348</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hd-l2.REF.ocampo.2018.126">Ocampo C, Daimari R, Oyekunle AA. Huntington's disease-like 2 with an expansion mutation of the Junctophilin-3 gene; first reported case from Botswana. <span><span class="ref-journal">J Clin Neurosci. </span>2018;<span class="ref-vol">47</span>:126–7.</span> [<a href="/pubmed/29066237" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29066237</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hd-l2.REF.rodrigues.2011.419">Rodrigues GR, Walker RH, Bader B, Danek A, Brice A, Cazeneuve C, Russaouen O, Lopes-Cendes I, Marques W Jr, Tumas V. Clinical and genetic analysis of 29 Brazilian patients with Huntington's disease-like phenotype. <span><span class="ref-journal">Arq Neuropsiquiatr. </span>2011;<span class="ref-vol">69</span>:419–23.</span> [<a href="/pubmed/21755114" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21755114</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hd-l2.REF.rosenblatt.1998.215">Rosenblatt A, Ranen NG, Rubinsztein DC, Stine OC, Margolis RL, Wagster MV, Becher MW, Rosser AE, Leggo J, Hodges JR, Ffrench-Constant CK, Sherr M, Franz ML, Abbott MH, Ross CA. Patients with features similar to Huntington's disease, without CAG expansion in huntingtin. <span><span class="ref-journal">Neurology. </span>1998;<span class="ref-vol">51</span>:215–20.</span> [<a href="/pubmed/9674805" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9674805</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hd-l2.REF.rudnicki.2007.272">Rudnicki DD, Holmes SE, Lin M, Thorton CA, Ross CA, Margolis RL. Huntington&#x02019;s disease-like 2 is associated with CUG repeat containing RNA foci. <span><span class="ref-journal">Ann Neurol. </span>2007;<span class="ref-vol">61</span>:272–82.</span> [<a href="/pubmed/17387722" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17387722</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hd-l2.REF.rudnicki.2008.366">Rudnicki DD, Pletnikova O, Vansattel JP, Ross CA, Margolis RL. A comparison of Huntington&#x02019;s disease and Huntington&#x02019;s disease-like 2 neuropathology. <span><span class="ref-journal">J Neuropathol Exp Neurol. </span>2008;<span class="ref-vol">67</span>:366–74.</span> [<a href="/pubmed/18379432" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18379432</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hd-l2.REF.seixas.2012.245">Seixas AI, Holmes SE, Takeshima H, Pavlovich A, Sachs N, Pruitt JL, Silveira I, Ross CA, Margolis RL, Rudnicki DD. Loss of junctophilin-3 contributes to Huntington disease-like 2 pathogenesis. <span><span class="ref-journal">Ann Neurol. </span>2012;<span class="ref-vol">71</span>:245–57.</span> [<a href="/pubmed/22367996" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22367996</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hd-l2.REF.stevanin.2002.965">Stevanin G, Camuzat A, Holmes SE, Julien C, Sahloul R, Dode C, Hahn-Barma V, Ross CA, Margolis RL, Durr A, Brice A. CAG/CTG repeat expansions at the Huntington's disease-like 2 locus are rare in Huntington's disease patients. <span><span class="ref-journal">Neurology. </span>2002;<span class="ref-vol">58</span>:965–7.</span> [<a href="/pubmed/11914418" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11914418</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hd-l2.REF.stevanin.2003.1599">Stevanin G, Fujigasaki H, Lebre AS, Camuzat A, Jeannequin C, Dode C, Takahashi J, San C, Bellance R, Brice A, Durr A. Huntington's disease-like phenotype due to trinucleotide repeat expansions in the TBP and JPH3 genes. <span><span class="ref-journal">Brain. </span>2003;<span class="ref-vol">126</span>:1599–603.</span> [<a href="/pubmed/12805114" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12805114</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hd-l2.REF.takeshima.2000.11">Takeshima H, Komazaki S, Nishi M, Iino M, Kangawa K. Junctophilins: a novel family of junctional membrane complex proteins. <span><span class="ref-journal">Mol Cell. </span>2000;<span class="ref-vol">6</span>:11–22.</span> [<a href="/pubmed/10949023" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10949023</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hd-l2.REF.walker.2018.10">Walker RH, Gatto EM, Bustamante ML, Bernal-Pacheco O, Cardoso F, Castilhos RM, Chana-Cuevas P, Cornejo-Olivas M, Estrada-Bellmann I, Jardim LB, L&#x000f3;pez-Castellanos R, L&#x000f3;pez-Contreras R, Maia DP, Mazzetti P, Miranda M, Rodr&#x000ed;guez-Violante M, Teive H, Tumas V. Huntington's disease-like disorders in Latin America and the Caribbean. <span><span class="ref-journal">Parkinsonism Relat Disord. </span>2018;<span class="ref-vol">53</span>:10–20.</span> [<a href="/pubmed/29853295" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29853295</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hd-l2.REF.walker.2003a.1527">Walker RH, Jankovic J, O'Hearn E, Margolis RL. Phenotypic features of Huntington's disease-like 2. <span><span class="ref-journal">Mov Disord. </span>2003a;<span class="ref-vol">18</span>:1527–30.</span> [<a href="/pubmed/14673892" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14673892</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hd-l2.REF.walker.2002.1031">Walker RH, Morgello S, Davidoff-Feldman B, Melnick A, Walsh MJ, Shashidharan P, Brin MF. Autosomal dominant chorea-acanthocytosis with polyglutamine-containing neuronal inclusions. <span><span class="ref-journal">Neurology. </span>2002;<span class="ref-vol">58</span>:1031–7.</span> [<a href="/pubmed/11940688" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11940688</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hd-l2.REF.walker.2003b.1002">Walker RH, Rasmussen A, Rudnicki D, Holmes SE, Alonso E, Matsuura T, Ashizawa T, Davidoff-Feldman B, Margolis RL. Huntington's disease-like 2 can present as chorea-acanthocytosis. <span><span class="ref-journal">Neurology. </span>2003b;<span class="ref-vol">61</span>:1002–4.</span> [<a href="/pubmed/14557581" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14557581</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hd-l2.REF.wilburn.2011.427">Wilburn B, Rudnicki DD, Zhao J, Weitz TM, Cheng Y, Gu X, Greiner E, Park CS, Wang N, Sopher BL, La Spada AR, Osmand A, Margolis RL, Sun YE, Yang XW. An antisense CAG repeat transcript at JPH3 locus mediates expanded polyglutamine protein toxicity in Huntington's disease-like 2 mice. <span><span class="ref-journal">Neuron. </span>2011;<span class="ref-vol">70</span>:427–40.</span> [<a href="/pmc/articles/PMC3107122/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3107122</span></a>] [<a href="/pubmed/21555070" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21555070</span></a>]</div></li></ul></div></div><div id="hd-l2.Chapter_Notes"><h2 id="_hd-l2_Chapter_Notes_">Chapter Notes</h2><div id="hd-l2.Author_Notes"><h3>Author Notes</h3><p>The laboratory of Dr Russell L Margolis at Johns Hopkins School of Medicine, which identified the first known family with HDL2 as well as the genetic cause, is actively investigating the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> and pathogenesis of HDL2 and welcomes questions regarding individuals possibly <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> with HDL2. Please contact Dr Margolis at rmargoli@jhmi.edu with questions or additional information about HDL2.</p><p>The Division of Human Genetics, at the National Health Laboratory Services and the School of Pathology, The University of the Witwatersrand is studying the detailed molecular genetics of the HDL2 <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and its association with clinical manifestations of HDL2, The laboratory will offer diagnostic testing for HDL2 for individuals from outside of South Africa. For further details, please contact Professor Amanda Krause at amanda.krause@wits.ac.za. Clinical questions can also be directed to Dr David Anderson at the University of Witwatersand, david@neuro.joburg.</p><p>The authors would like to be informed of all newly diagnosed individuals with HDL2 to expand information about this rare disease.</p></div><div id="hd-l2.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>27 June 2019 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>26 April 2012 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>13 August 2009 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>10 March 2006 (me) Comprehensive update review posted live</div></li><li class="half_rhythm"><div>30 January 2004 (me) Review posted live</div></li><li class="half_rhythm"><div>15 September 2003 (rm) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1529</span><span class="label">PMID: <a href="/pubmed/20301701" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301701</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/huntington/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/huppke-brendel/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1529&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1529/?report=reader">PubReader</a></li><li><a href="/books/NBK1529/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1529" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1529" style="display:none" title="Cite this Page"><div class="bk_tt">Anderson DG, Krause A, Margolis RL. Huntington Disease-Like 2. 2004 Jan 30 [Updated 2019 Jun 27]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1529/pdf/Bookshelf_NBK1529.pdf">PDF version of this page</a> (454K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#hd-l2.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#hd-l2.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#hd-l2.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#hd-l2.Genetically_Related_Allelic_Disord" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#hd-l2.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#hd-l2.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#hd-l2.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#hd-l2.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#hd-l2.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#hd-l2.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#hd-l2.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=57338[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">JPH3</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1472560" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1472560" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1472560" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1472560" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301482" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Huntington Disease</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Huntington Disease<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Caron NS, Wright GEB, Hayden MR. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26079385" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Junctophilin 3 (JPH3) expansion mutations causing Huntington disease like 2 (HDL2) are common in South African patients with African ancestry and a Huntington disease phenotype.</a><span class="source">[Am J Med Genet B Neuropsychiat...]</span><div class="brieflinkpop offscreen_noflow">Junctophilin 3 (JPH3) expansion mutations causing Huntington disease like 2 (HDL2) are common in South African patients with African ancestry and a Huntington disease phenotype.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Krause A, Mitchell C, Essop F, Tager S, Temlett J, Stevanin G, Ross C, Rudnicki D, Margolis R. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Am J Med Genet B Neuropsychiatr Genet. 2015 Oct; 168(7):573-85. Epub 2015 Jun 16.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301363" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spinocerebellar Ataxia Type 1</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spinocerebellar Ataxia Type 1<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Opal P, Ashizawa T. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/22367996" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Loss of junctophilin-3 contributes to Huntington disease-like 2 pathogenesis.</a><span class="source">[Ann Neurol. 2012]</span><div class="brieflinkpop offscreen_noflow">Loss of junctophilin-3 contributes to Huntington disease-like 2 pathogenesis.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Seixas AI, Holmes SE, Takeshima H, Pavlovich A, Sachs N, Pruitt JL, Silveira I, Ross CA, Margolis RL, Rudnicki DD. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Ann Neurol. 2012 Feb; 71(2):245-57. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301445" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spinocerebellar Ataxia Type 8</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spinocerebellar Ataxia Type 8<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Ayhan F, Ikeda Y, Dalton JC, Day JW, Ranum LPW. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301701" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301701" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5dfc95a139a66ee2ba64b91b">Huntington Disease-Like 2 - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Huntington Disease-Like 2 - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-20T04:34:25-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal103&amp;ncbi_phid=CE8AC4A5DFC86971000000000768039A&amp;ncbi_session=CE8AC4A5DFC95A11_1896SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1529%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1529&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1529/&amp;ncbi_pagename=Huntington Disease-Like 2 - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8AC4A5DFC95A11_1896SID /projects/books/PBooks@5.22 portal103 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>